Harbor Investment Advisory LLC Grows Stake in Edwards Lifesciences Co. (NYSE:EW)

Harbor Investment Advisory LLC lifted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,825 shares of the medical research company’s stock after purchasing an additional 1,442 shares during the period. Harbor Investment Advisory LLC’s holdings in Edwards Lifesciences were worth $1,320,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences in the third quarter worth $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth $32,000. Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the last quarter. Peoples Bank KS bought a new stake in Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,000 shares of company stock valued at $2,195,180. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $69.77 on Tuesday. The company’s fifty day moving average is $72.06 and its 200 day moving average is $71.18. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $41.15 billion, a PE ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 EPS. Research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Barclays increased their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.